Fundraising Fox

Inversago

acquired by Novo Nordisk

5 known investors

Portfolio company acquired by Novo Nordisk for $1.1B USD.

Investors · 5

AmorChemMontreal
Genesys CapitalToronto · $730K – $3.6M
JDRF T1D FundBoston
New Enterprise Associates (NEA)Menlo Park · $200K – $40M
Tarnagulla VenturesMelbourne

In the news

Novo adds another obesity drug in $1B deal for startup Inversago | BioPharma Divebiopharmadive.com · Aug 2023Montreal’s Inversago raises $95-million led by NEA to revive failed class of weight-loss drugs - The Globe and Mailtheglobeandmail.com · Oct 2022Inversago Pharma Raises $95 million CAD in Series C Financingbusinesswire.com · Oct 2022Inversago Pharma Closes US$35M Series B Financing Round and Expands Board of Directors | Business Wirebusinesswire.com · Sep 2020Inversago Pharma Raises $35 Million to Fund CB1-based Pipeline - Global Genesglobalgenes.org · Sep 2020Canada’s Inversago raises $7M to target cannabinoid receptors | Fierce Biotechfiercebiotech.com · Jul 2018

Frequently asked questions

What does Inversago do?
Portfolio company acquired by Novo Nordisk for $1.1B USD.
Who are Inversago's investors?
Inversago's investors include AmorChem, Genesys Capital, JDRF T1D Fund, New Enterprise Associates (NEA), Tarnagulla Ventures.
Who acquired Inversago?
Inversago was acquired by Novo Nordisk.